Dan Atar, MD

Dan Atar, MD

Head of Research

Oslo University Hospital Ulleval

Professors of Cardiology

University of Oslo 

Oslo, Norway

Visiting Associate Professorship 

Johns Hopkins University

Baltimore, Maryland

Related Videos

Given the new AHA Guidelines and the anticipation of new ESC Guidelines in 2019, what is your view about LDL-C level target thresholds vs. degree of LDL-C reduction? What level do you consider optimal in high-risk patients with progressive ASCVD? Video

Given the new AHA Guidelines and the anticipation of new ESC Guidelines in 2019, what is your view about LDL-C level target thresholds vs. degree of LDL-C reduction? What level do you consider optimal in high-risk patients with progressive ASCVD?

What are the current challenges and protocols in Europe for making PCSK9 inhibitors an easily reimbursable, “mainstream” approach to managing patients with require secondary prevention for their high-risk ASCVD? Video

What are the current challenges and protocols in Europe for making PCSK9 inhibitors an easily reimbursable, “mainstream” approach to managing patients with require secondary prevention for their high-risk ASCVD?

Does the presence of a stent in the setting of ACS color your approach to the degree of LDL-C reduction you would pursue? Video

Does the presence of a stent in the setting of ACS color your approach to the degree of LDL-C reduction you would pursue?

What is the current unmet need for CV risk reduction, in general, beyond LDL-C level lowering? Video

What is the current unmet need for CV risk reduction, in general, beyond LDL-C level lowering?

Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering? Video

Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor? Video

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?